Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation

Overview

Journal J Neurosci

Specialty Neurology

Date 2005 Feb 25

PMID 15728830

Citations 278

Authors

Belen G Ramirez

Cristina Blazquez

Teresa Gomez del Pulgar

Manuel Guzman

Maria L de Ceballos

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) is characterized by enhanced beta-amyloid peptide (betaA) deposition along with glial activation in senile plaques, selective neuronal loss, and cognitive deficits. Cannabinoids are neuroprotective agents against excitotoxicity in vitro and acute brain damage in vivo. This background prompted us to study the localization, expression, and function of cannabinoid receptors in AD and the possible protective role of cannabinoids after betaA treatment, both in vivo and in vitro. Here, we show that senile plaques in AD patients express cannabinoid receptors CB1 and CB2, together with markers of microglial activation, and that CB1-positive neurons, present in high numbers in control cases, are greatly reduced in areas of microglial activation. In pharmacological experiments, we found that G-protein coupling and CB1 receptor protein expression are markedly decreased in AD brains. Additionally, in AD brains, protein nitration is increased, and, more specifically, CB1 and CB2 proteins show enhanced nitration. Intracerebroventricular administration of the synthetic cannabinoid WIN55,212-2 to rats prevent betaA-induced microglial activation, cognitive impairment, and loss of neuronal markers. Cannabinoids (HU-210, WIN55,212-2, and JWH-133) block betaA-induced activation of cultured microglial cells, as judged by mitochondrial activity, cell morphology, and tumor necrosis factor-alpha release; these effects are independent of the antioxidant action of cannabinoid compounds and are also exerted by a CB2-selective agonist. Moreover, cannabinoids abrogate microglia-mediated neurotoxicity after betaA addition to rat cortical cocultures. Our results indicate that cannabinoid receptors are important in the pathology of AD and that cannabinoids succeed in preventing the neurodegenerative process occurring in the disease.

Citing Articles

Chronic exposure to a synthetic cannabinoid improves cognition and increases locomotor activity in Tg4-42 Alzheimer's disease mice.

Ott F, Sichler M, Bouter C, Enayati M, Wiltfang J, Bayer T J Alzheimers Dis Rep. 2025; 9:25424823241306770.

PMID: 40034517 PMC: 11869267. DOI: 10.1177/25424823241306770.

Phytocanabinoids and synthetic cannabinoids: from recreational consumption to potential therapeutic use - a review.

Teixeira H Front Toxicol. 2025; 6:1495547.

PMID: 39936019 PMC: 11810933. DOI: 10.3389/ftox.2024.1495547.

Exploring the diversity of cannabis cannabinoid and non-cannabinoid compounds and their roles in Alzheimer's disease: A review.

Doumar H, Mostafi H, Elhessni A, Touhami M, Mesfioui A IBRO Neurosci Rep. 2025; 18:96-119.

PMID: 39866750 PMC: 11763173. DOI: 10.1016/j.ibneur.2024.12.011.

Cannabinoids: Role in Neurological Diseases and Psychiatric Disorders.

Kumar U Int J Mol Sci. 2025; 26(1.

PMID: 39796008 PMC: 11720483. DOI: 10.3390/ijms26010152.

Intranasal Treatment with Cannabinoid 2 Receptor Agonist HU-308 Ameliorates Cold Sensitivity in Mice with Traumatic Trigeminal Neuropathic Pain.

Ma S, Nakamura Y, Uemoto S, Yamamoto K, Hisaoka-Nakashima K, Morioka N Cells. 2024; 13(23).

PMID: 39682692 PMC: 11640163. DOI: 10.3390/cells13231943.

References

Waksman Y, Olson J, Carlisle S, Cabral G . The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells. J Pharmacol Exp Ther. 1999; 288(3):1357-66. View

Lan R, Liu Q, Fan P, Lin S, Fernando S, McCallion D . Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J Med Chem. 1999; 42(4):769-76. DOI: 10.1021/jm980363y. View

Nagayama T, Sinor A, Simon R, Chen J, Graham S, Jin K . Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci. 1999; 19(8):2987-95. PMC: 6782289. View

Ong W, Mackie K . A light and electron microscopic study of the CB1 cannabinoid receptor in primate brain. Neuroscience. 1999; 92(4):1177-91. DOI: 10.1016/s0306-4522(99)00025-1. View

Lee S, Zhao M, Hirano A, Dickson D . Inducible nitric oxide synthase immunoreactivity in the Alzheimer disease hippocampus: association with Hirano bodies, neurofibrillary tangles, and senile plaques. J Neuropathol Exp Neurol. 1999; 58(11):1163-9. DOI: 10.1097/00005072-199911000-00006. View

Puffenbarger R, Boothe A, Cabral G . Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia. 1999; 29(1):58-69. View

Pavia J, Alberch J, Alvarez I, Toledano A, de Ceballos M . Repeated intracerebroventricular administration of beta-amyloid(25-35) to rats decreases muscarinic receptors in cerebral cortex. Neurosci Lett. 2000; 278(1-2):69-72. DOI: 10.1016/s0304-3940(99)00900-3. View

Huffman J, Liddle J, Yu S, Aung M, Abood M, Wiley J . 3-(1',1'-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg Med Chem. 2000; 7(12):2905-14. DOI: 10.1016/s0968-0896(99)00219-9. View

Aoyama K, Matsubara K, Fujikawa Y, Nagahiro Y, Shimizu K, Umegae N . Nitration of manganese superoxide dismutase in cerebrospinal fluids is a marker for peroxynitrite-mediated oxidative stress in neurodegenerative diseases. Ann Neurol. 2000; 47(4):524-7. View

10.

Glass M, Dragunow M, Faull R . The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience. 2000; 97(3):505-19. DOI: 10.1016/s0306-4522(00)00008-7. View

11.

Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole G . Inflammation and Alzheimer's disease. Neurobiol Aging. 2000; 21(3):383-421. PMC: 3887148. DOI: 10.1016/s0197-4580(00)00124-x. View

12.

Bard F, Cannon C, Barbour R, Burke R, Games D, Grajeda H . Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000; 6(8):916-9. DOI: 10.1038/78682. View

13.

Herrera A, Castano A, Venero J, Cano J, Machado A . The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiol Dis. 2000; 7(4):429-47. DOI: 10.1006/nbdi.2000.0289. View

14.

Tan J, Town T, Mori T, Wu Y, Saxe M, Crawford F . CD45 opposes beta-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activated protein kinase. J Neurosci. 2000; 20(20):7587-94. PMC: 6772874. View

15.

Hampson A, Grimaldi M . Cannabinoid receptor activation and elevated cyclic AMP reduce glutamate neurotoxicity. Eur J Neurosci. 2001; 13(8):1529-36. DOI: 10.1046/j.0953-816x.2001.01536.x. View

16.

Wyss-Coray T, Lin C, Yan F, Yu G, Rohde M, McConlogue L . TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat Med. 2001; 7(5):612-8. DOI: 10.1038/87945. View

17.

Breivogel C, Griffin G, Di Marzo V, Martin B . Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol. 2001; 60(1):155-63. View

18.

Matsuoka Y, Picciano M, La Francois J, Duff K . Fibrillar beta-amyloid evokes oxidative damage in a transgenic mouse model of Alzheimer's disease. Neuroscience. 2001; 104(3):609-13. DOI: 10.1016/s0306-4522(01)00115-4. View

19.

Sanchez C, de Ceballos M, Gomez Del Pulgar T, Rueda D, Corbacho C, Velasco G . Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res. 2001; 61(15):5784-9. View

20.

van der Stelt M, Veldhuis W, Bar P, Veldink G, Vliegenthart J, Nicolay K . Neuroprotection by Delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. J Neurosci. 2001; 21(17):6475-9. PMC: 6763099. View